BoomRay licenses preclinical radioligand asset to Novartis for up to $900 million
AI Summary- Boomray Pharmaceuticals granted Novartis an exclusive global license for an undisclosed preclinical RLT asset.
- BoomRay is eligible for up to $900 million, plus potential royalties on future global net sales.
- BFC Group acted as BoomRay’s financial adviser in the agreement.